Explore the latest news from national and international oncology congresses and remain at the forefront of latest clinical innovation and advances in oncology and haematology. Each SPECIAL ISSUE – CONGRESS REPORT features comprehensive summaries of the key topics from lung cancer, solid tumours & haematology research to come out of a major national and international oncology congress.
The memo inOncology Medical education series: keeping oncologists at the forefront of solid tumour research. memo-inOncology Special Issue Preceptorship reports summarise the latest information in solid tumour research and treatments to based on our sponsored Preceptorship meeting series. The fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.
Springer is delighted to announce a new memo inOncology SPECIAL ISSUE congress report from this years ASCO and ESMO!
memo – inOncology SPECIAL ISSUE in
Congress Report ESMO 2019
|memo – inOncology SPECIAL ISSUE in|
advanced Solid Tumours
Congress Report ESMO 2019
This report summarizes a selection of abstracts presented at ESMO 2019 in the areas of advanced Solid Tumours.
Expert interviews at ESMO 2019 – Lung Cancer
Filippo de Braud explains what can be achieved with TRK inhibition in TRK-fusion-positive NSCLC, indirectly compares the performance of entrectinib to crizotinib in ROS1-positive disease and shares his opinion on the intracranial activity of entrectinib.
Michael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.
Stephen Liu on the latest insights in the field of ALK-targeted treatment in lung cancer, a recent update on the clinical evaluation of NRG1-directed therapies, as well as novel molecular targets for lung cancer treatment in the foreseeable future.
Ioannis Metaxas talks about the rationale for the evaluation of lurbinectedin in malignant pleural mesothelioma, the clinical results with lurbinectedin in patients with mesothelioma to date and other areas of lung cancer treatment in which lurbinectedin might prove useful in the future.
Expert interviews at ESMO 2019 – Solid Tumours
Dr. Arkenau discusses combination studies of novel PARP inhibitors with other drugs.
Dr. Lordick on the use of anti-PD-1 and other emerging therapies in gastric and oesophageal cancers.
Dr. Möhler presents novel findings on anti-PD-1 therapies and explains differences regarding the outcome of anti-PD-1 therapies in Asian and Caucasian populations.
Dr. Chowdhury talks about the use of PARP inhibitors in prostate cancer as well as the impact of pamiparib in patients with advanced solid tumors.